Want FREE Templates on Digital Transformation? Download our FREE compilation of 50+ slides. This is an exclusive promotion being run on LinkedIn.

  Please register (it's free!) or login to view the remaining preview.
If you are logged in, your referral link [?] is automatically included below.
EMBED CODE (Copy and Paste)


  1. In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal


In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal junction (GEJ) adenocarcinoma. We expect that major-market sales will rapidly increase over the forecast period, totaling almost $9.5 billion in 2025. This growth will be predominantly fuelled by the approval of seven agents in the indication, and also by Cyramza (Eli Lilly?s ramucirumab).

The entry of three PD-1/PD-L1 inhibitors into the gastric and GEJ adenocarcinoma market (Merck & Co.?s Keytruda [pembrolizumab], Bristol Myers-Squibb/Ono Pharmaceutical?s Opdivo [nivolumab], and Merck KGaA/Pfizer?s avelumab) will significantly drive growth during the forecast period. We also forecast the approval of Yervoy (Bristol Myers-Squibb/Ono Pharmaceutical?s ipilimumumab) to be used in conjunction with Opdivo. In addition, we anticipate the launch of a next generation HER2-targeting therapy (Roche/Genentech/Chugai?s Perjeta [pertuzumab]), a cancer 'stemness' inhibitor (Boston Biomedical?s napabucasin), and a MMP-9 inhibitor (Gilead Sciences? GS-5745). Collectively, these agents will contribute 80% of total sales in the gastric and GEJ adenocarcinoma in 2025.

Key Findings
Market Share of Gastric Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at [email protected] or ask the author directly by using the form to the right. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Market Overview: Gastric Cancer PowerPoint document


Market Overview: Gastric Cancer

Sold by pharmzolgas (this author has 4 documents)


Add to Cart

This business document is categorized under the function(s):

It applies to Healthcare & Life Sciences

File Type: PowerPoint (pptx)

File Size: 2.4 MB

Number of Slides: 27 (includes cover, transition slides)

Purchase includes lifetime product updates. After your purchase, you will receive an email to download this document.

Initial upload date (first version): Mar 8, 2017
Most recent version published: Mar 10, 2017

Ask the Author a Question

Must be logged in Click here to log in



Since 2012, we have provided best practices to over 5,000 businesses and organizations of all sizes across the world—in over 130 countries. Below is just a very small sample of our customer base.

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.


1-page PDF document
Author: Ivana Nissen
234-slide PowerPoint deck
Author: Ivana Nissen
1-page PDF document
901-slide PowerPoint deck
50-slide PowerPoint deck
57-slide PowerPoint deck
29-page Word document
Author: gmclennan
232-slide PowerPoint deck and supporting ZIP



Become your organization's resident expert on...

Digital Transformation
Strategy Development
Organizational Design (OD)
Performance Management
Post-merger Integration (PMI)
Organizational Culture (OC)
Business Transformation
Customer-centric Design (CCD)
Interested in something else? Browse our 350+ Business Toolkits of best practices, each focused on a specific management topic.